Management of castration-resistant, taxane-resistant prostate cancer

Tomasz (Tom) Beer

    Research output: Contribution to journal › Article

    Abstract

    Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

    Original languageEnglish (US)
    Pages (from-to)1-5
    Number of pages5
    JournalONCOLOGY (United States)
    Volume31
    Issue number8
    StatePublished - Aug 15 2017

    Fingerprint

    Castration
    docetaxel
    Prostatic Neoplasms
    Disease Management
    Drug Therapy
    Survival
    Therapeutics
    Neoplasms
    taxane

    ASJC Scopus subject areas

    • Medicine(all)
    • Oncology
    • Cancer Research

    Cite this

    Management of castration-resistant, taxane-resistant prostate cancer. / Beer, Tomasz (Tom).

    In: ONCOLOGY (United States), Vol. 31, No. 8, 15.08.2017, p. 1-5.

    Research output: Contribution to journal › Article

    Beer, TT 2017, 'Management of castration-resistant, taxane-resistant prostate cancer', ONCOLOGY (United States), vol. 31, no. 8, pp. 1-5.
    Beer TT. Management of castration-resistant, taxane-resistant prostate cancer. ONCOLOGY (United States). 2017 Aug 15;31(8):1-5.
    Beer, Tomasz (Tom). / Management of castration-resistant, taxane-resistant prostate cancer. In: ONCOLOGY (United States). 2017 ; Vol. 31, No. 8. pp. 1-5.
    @article{8e9c2a972b664f15b20b4c4f615326e9,
    title = "Management of castration-resistant, taxane-resistant prostate cancer",
    abstract = "Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.",
    author = "Beer, {Tomasz (Tom)}",
    year = "2017",
    month = "8",
    day = "15",
    language = "English (US)",
    volume = "31",
    pages = "1--5",
    journal = "ONCOLOGY (United States)",
    issn = "0890-9091",
    publisher = "UBM Medica Healthcare Publications",
    number = "8",

    }

    TY - JOUR

    T1 - Management of castration-resistant, taxane-resistant prostate cancer

    AU - Beer, Tomasz (Tom)

    PY - 2017/8/15

    Y1 - 2017/8/15

    N2 - Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

    AB - Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

    UR - http://www.scopus.com/inward/record.url?scp=85027701071&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85027701071&partnerID=8YFLogxK

    M3 - Article

    VL - 31

    SP - 1

    EP - 5

    JO - ONCOLOGY (United States)

    JF - ONCOLOGY (United States)

    SN - 0890-9091

    IS - 8

    ER -

    Access to Document